Abstract: A composition comprising effective amounts of benzalkonium chloride, allantoin, and nitrofurazone in a water soluble base for treating wounds and skin conditions, such as dermatitis is described. Methods of treating skin conditions and accelerating wound healing are also described.

Abstract: Compositions and methods are provided that are effective in treating skin hyperproliferative disorders. These include a topical pharmaceutical preparation that includes a compound that has two or more of a SRC-kinase inhibiting activity, a tubulin polymerization inhibiting activity, an activity that arrests the cell cycle at G2/M, and an activity that induces apoptosis. The compound KX01 is provided as an example of such a compound. The topical pharmaceutical preparation further includes a vitamin D derivative or a retinoid, where the combination provides a synergistic effect. Use of the topical pharmaceutical preparation can be combined with exposure to blue, UVA, or UVB light, which provides a synergistic effect.

Abstract: Provided is a cosmetic excelling in terms of reduction of oil weight, reduction of powder weight, improvement of dispersion stability, and dispersion stability. The cosmetic contains a metal oxide having an average particle diameter of 0.01 ?m to 0.1 ?m, a paste oil including a hydrophilic group, and an acrylates/ethylhexyl acrylate/dimethicone methacrylate copolymer.

Abstract: Provided are a cosmetic composition for promoting lipid biosynthesis, a cosmetic composition for inducing differentiation of adipose precursor cells or stem cells into adipocytes, and a cosmetic composition for moisturizing the skin, all of which include an amide-based compound. The cosmetic composition according to the present invention can promote the lipid biosynthesis and can promote expression of PPAR-? and cluster of differentiation 44, which are markers for labeling human adipose tissue-derived stem cells, to promote differentiation of the adipose tissue-derived stem cells into mature adipocytes, thereby improving a decreased volume and an impaired function of an adipose tissue caused due to the involution of the adipose tissue and giving a synergistic effect to the expression of a skin moisturizing factor.

Abstract: The present disclosure relates to the discovery that certain diseases of the eye that profoundly affect the human visual system and, as a result, quality of life, may be treated using Edonentan or A-182086. Edonentan or A-182086 can be used alone or in combination with an intra-ocular pressure (IOP) reducing agent, a neuroprotective agent, an anti-VEGF agent, or all, for example. Using Edonentan or A-182086, alone or in combination with an additional agent, provides increased perfusion to the retina in certain diseases and reduces damage to retinal cells.

Abstract: The invention relates to an orally disintegrating nicotine tablet for nicotine craving relief comprising a pressed powder formulation, the tablet being designed to disintegrate within a period of less than 60 seconds upon oral administration, the powder formulation comprising an amount of nicotine and a pH regulating agent.

Abstract: The present invention provides a technique that allows a pharmaceutical composition, preferably for external use, containing luliconazole or the like to contain luliconazole or the like at a high concentration, and suppresses the precipitation thereof over time. The present invention uses a polyethylene glycol having an average molecular weight of 380 to 420 represented by a formula HOCH2(CH2OCH2)nCH2OH (where n is an integer), ethanol, benzyl alcohol, lactic acid, propylene carbonate, and acetone in combination with the luliconazole or the like.

Abstract: The present invention relates to zirconium silicate compositions having a lead content that is below 0.6 ppm and methods of manufacturing zirconium silicate at reactor volumes exceeding 200-L with a lead content below 1.1 ppm. The lead content of the zirconium silicate of this invention are within the levels that are considered acceptable for extended use given the dose requirements for zirconium silicate.

Abstract: Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a reduction in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and/or nitrate.

Abstract: The present invention discloses a method for preparing a lycopene micro-capsule powder, wherein lycopene is fully mixed with an aqueous phase to obtain a lycopene emulsion, and the emulsion is then ground to a particle size less than 1 ?m, and spray dried. The aqueous phase comprises: a gelatin enzymatic hydrolysate with a molecular weight of 5,000-10,000 Da, disaccharide, polysaccharide, and an antioxidant. The disaccharide is one or more of sucrose, maltose and lactose; and the polysaccharide is one or more of pullulan and chitosan.

Abstract: By determining the lethality rate to Meloidogyne incognita and Caenorhabditis elegans, it was found that the methylmalonic acid has a better nematicidal effect on the Caenorhabditis elegans, with the LC50 being 13.11 and 1.20 for the Meloidogyne incognita and the Caenorhabditis elegans, respectively. After compounding the methylmalonic acid with betaine, the LC50 was 2.85 and 0.27 for the Meloidogyne incognita and the Caenorhabditis elegans, respectively. Meanwhile, the methylmalonic acid also has an inhibiting effect on Pseudomonas solanacearum and Erwinia carotovora. The preparation of the methylmalonic acid provides a new choice for preparing novel biocontrol agents against the root-knot nematodes.

Abstract: The present invention relates in part to novel drug delivery particles comprising an anionic polymer matrix and a cationic polymer, wherein the anionic polymer matrix and cationic polymer together form drug delivery particles bound by electrostatic interactions and wherein the drug delivery particles comprise at least one biologically active agent. The invention also relates in part to a method of treating a mycobacterial infection using said drug delivery particles, and a method of making said drug delivery particles.

Abstract: There are provided an enteric coating composition having an excellent film-forming property, being capable of forming a film at a lower temperature than conventional compositions, and/or being capable of avoiding decomposition of a drug due to a high temperature and operational troubles due to or nozzle clogging; and others. More specifically, there are provided an enteric coating composition containing hypromellose acetate succinate having a molar substitution of hydroxypropoxy groups of 0.40 or more, and water; a method for producing a solid preparation including steps of coating a drug-containing core with the enteric coating composition to obtain a coating layer, and drying the coating layer; and a solid preparation containing a drug-containing core, and a coating layer directly or indirectly on the core, the coating layer containing a hypromellose acetate succinate having a molar substitution of hydroxypropoxy groups of 0.40 or more.

Abstract: The present invention is directed to compositions and methods for preventing and/or treating diseases and disorders of patients caused by non-Staphylococcal microorganisms. In particular, compositions and methods contain lysostaphin, altered forms of lysostaphin as compared to wild-type, and synergistic combinations of lysostaphin plus additional conventional treatments such as other enzyme, antibiotic and/or antibody treatment. The invention is also directed to detecting and identifying altered forms of lysostaphin that possess increased efficacy against infections as compared to wild-type lysostaphin, and forms that generate a minimal or no immune response in a patient. The invention is also directed to method of manufacturing lysostaphin and altered forms of lysostaphin, and compositions that direct the lysostaphin to the site of the infection such as aerosolized nanoparticles.

Abstract: An anticoccidial disinfection formulation containing a compound represented by general formula (I) below as an active ingredient: R1—N?C?S ??(I) [In formula (I), R1 represents an alkenyl group having 2 to 8 carbon atoms or the like] This compound has a high sporulation inhibitory activity against coccidian oocysts and is thus effective for eradicating coccidians and for disinfecting rearing facilities and rooms of host animals, such as a livestock barn and a poultry house.

Abstract: Provided herein is a pharmaceutical composition for treating cancers. The pharmaceutical composition includes an oil-in-water (o/w) microemulsion, and an active pharmaceutical ingredient dissolved therein. The o/w microemulsion is comprised of an aqueous solution, an oil, and a surfactant, and is about 5-250 nm in diameter. Also provided herein are methods for treating cancers by use of the present pharmaceutical composition.

Abstract: Methods of synthesizing Bi2S3—CdS particles in the form of spheres as well as properties of these Bi2S3—CdS particles are described. Methods of photocatalytic degradation of organic pollutants employing these Bi2S3—CdS particles and methods of preventing or reducing microbial growth on a surface by applying these Bi2S3—CdS particles in the form of a solution or an antimicrobial product onto the surface are also specified.

Abstract: The present invention is directed to an herbicidal composition comprising metribuzin, flumioxazin, pyroxasulfone, a salting-out agent and polyvinyl alcohol. The present invention is further directed to a method of controlling weeds comprising applying a composition of the present invention to the weeds or an area in need of weed control.

Abstract: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein (DIPA-1-5, DIPA-1-6, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”) that are useful, for example, in the treatment of disorders (e.g., diseases) including: sensory discomfort (e.g., caused by irritation, itch, or pain); a skin dysesthesia; dermatitis; psoriasis; ocular discomfort; heat discomfort; heat stress; flushing and/or night sweats (vasomotor symptoms) in post-menopausal women; post-operative hypothermia; post-anaesthetic shivering; fatigue; tiredness; depression; cognitive dysfunction; and to enhance cognitive function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.

Abstract: A drug and layered silicate composite is provided. The drug and layered silicate contains layered silicate powders and a drug compound bound to between layers of the silicate powders, wherein the drug compound is present in an amorphous state in the composite. Using such a composite may significantly improve absorption and bioavailability of a sorafenib compound.